<DOC>
	<DOCNO>NCT00686478</DOCNO>
	<brief_summary>This study assess intervention antifibrotic agent , specifically interferon ( IFN ) reduce magnitude duration hypertrophic scar . Burn patient hypertrophic scar randomly assign either intervention IFN group placebo control group subcutaneous injection three time week . Patients assess use cutometer , mexameter , standardize photography , urinalysis , blood work , tissue biopsy Vancouver Burn Scar Assessment ( VBSA ) rate select HTS base color , vascularity , height , pliability , itchiness pain sensitivity . Once treatment patient assess monthly six month treatment period .</brief_summary>
	<brief_title>Intron A Treatment Hypertrophic Scar</brief_title>
	<detailed_description>Burn patient follow treated Outpatient Burn Clinic large area HTS approach participate study . Patients agree participate sign informed consent enter trial . Pre-treatment evaluation monthly examination include : - standardize photograph scar - scar volume - Vancouver Burn Scar Assessment ( VBSA ) - blood work ( TGF-beta , histamine ) - urine collection ( histamine ) - 6mm punch biopsy HTS adjacent normal skin ( every two month ) Patients randomize receive placebo Intron A 1x106 IU day 7 day , 3x106 IU 3 SC , three time week 23 week .</detailed_description>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cicatrix , Hypertrophic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>burn &gt; 5 % tbsa inform consent prior exposure interferon cytokine history cardiac CNS disorder disease autoimmune disease immunodeficiency abnormal renal hepatic function pregnancy serious intercurrent illness active infection malnutrition active drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>burn</keyword>
	<keyword>hypertrophic scar</keyword>
	<keyword>fibroproliferative disorder</keyword>
</DOC>